特立帕肽和地舒单抗序贯治疗对老年骨质疏松症患者生活质量和骨相关血清标志物的影响

Effects of sequential treatment with teriparatide and denosumab on quality of life and bone-related serum markers in elderly patients with osteoporosis

中文关键词: 老年  骨质疏松症  特立帕肽  地舒单抗  序贯治疗  疗效  生活质量  骨相关血清标志物

英文关键词: elderly  osteoporosis  teriparatide  denosumab  sequential treatment  efficacy  quality of life  bone related serum markers

中文摘要:

      目的 观察特立帕肽和地舒单抗序贯治疗老年骨质疏松症(OP)的疗效及对患者生活质量和骨相关血清标志物的影响.方法 选取2021年3月—2022年3月陕西省核工业二一五医院收治的86例老年OP患者作为研究对象,按治疗方法分为观察组43例(特立帕肽和地舒单抗序贯治疗)和对照组43例(地舒单抗治疗).比较2组临床疗效、生活质量、骨相关血清标志物、骨密度值以及不良反应发生情况.结果 治疗后,观察组疗效高于对照组(P＜0.05);观察组SF-36量表评分、血钙、血磷水平及腰椎、全髋、股骨颈的骨密度值均高/大于对照组(P＜0.05),Ⅰ型前胶原氨基端前肽(P1NP)、Ⅰ型胶原交联C-末端肽(CTX)水平低于对照组(P＜0.05).结论 特立帕肽地舒单抗序贯治疗老年OP的疗效可能更显著,可显著增加骨密度,降低骨折风险,并改善患者生活质量和骨相关血清标志物水平,且安全性高,具有一定的临床应用价值.

英文摘要:

      Objective To explore the efficacy of sequential treatment with teriparatide and denosumab in elderly pa-tients with osteoporosis(OP)and its impacts on quality of life and bone related serum markers.Methods 86 elderly OP pa-tients treated in Hospital 215 of Shaanxi Nuclear Industry from March 2021 to March 2022 were enrolled as the research sub-jects.According to the treatment methods,they were divided into observation group(n=43,sequential treatment with teripa-ratide and denosumab)and control group(n=43,treatment with denosumab).The clinical efficacy,quality of life,bone-re-lated serum markers,bone mineral density values and the occurrence of adverse reactions were compared between the two groups.Results After the treatment,the therapeutic effect of the observation group was significantly higher than that of the control group(P＜0.05).The SF-36 scale score,levels of blood calcium and blood phosphorus,and bone mineral density val-ues of the lumbar vertebrae,total hip,and femoral neck in the observation group were all higher/greater than those in the con-trol group(P＜0.05),while the levels of type Ⅰ procollagen amino-terminal propeptide(P1NP)and type Ⅰ collagen cross-linked C-terminal peptide(CTX)were lower than those in the control group(P＜0.05).Conclusion The sequential treat-ment wtih teriparatide and desumab in elderly OP patients may have a more significant therapeutic effect.It can significantly in-crease bone mineral density,reduce the risk of fractures,and improve the quality of life and bone-related serum marker levels of patients.Moreover,it has high safety and certain clinical application value.